Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach

Journal of Medicinal Chemistry

Volumn 51, Issue 19, 2008, Pages 6138-6149

  Lucas, Simon ^a   Heim, Ralf ^a   Negri, Matthias ^a   Antes, Iris ^b   Ries, Christina ^a   Schewe, Katarzyna E ^a   Bisi, Alessandra ^c   Gobbi, Silvia ^c   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 BENZYLNAPHTHALEN 2 YL)PYRIDINE; 3 (3 PHENYLNAPHTHALEN 2 YL)PYRIDINE; 3 [6 METHOXY 3 (4 METHOXYBENZYL)NAPHTHALEN 2 YL]PYRIDINE; 4 (3 PYRIDIN 3 YL NAPHTHALEN 2 YLMETHYL)BENZONITRILE; ALDOSTERONE SYNTHASE; ALDOSTERONE SYNTHASE INHIBITOR; AROMATASE; AROMATIC COMPOUND; BENZENE DERIVATIVE; BENZYL DERIVATIVE; CYTOCHROME P450 17; FADROZOLE; HEME; IRON; LIGAND; NAPHTHALENE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HYDROPHOBICITY; IC 50; MOLECULAR DOCKING; NONHUMAN; PHARMACOPHORE;

ACIDS, CARBOCYCLIC; ALDOSTERONE SYNTHASE; BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHALENES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53549099432     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800683c     Document Type: Article

References (55)

1. Kawamoto, T.; Mitsuuchi, Y.; Toda, K.; Yokoyama, Y.; Miyahara, K.; Miura, S.; Ohnishi, T.; Ichikawa, Y.; Nakao, K.; Imura, H.; Ulick, S.; Shizuta, Y. Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 1458-1462.
2. (a) Brilla, C. G. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc. Res. 2000, 47, 1-3.
3. (b) Lijnen, P.; Petrov, V. Induction of cardiac fibrosis by aldosterone. J. Mol. Cell. Cardiol. 2000, 32, 865-879.
4. (a) Struthers, A. D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J. Card. Fail. 1996, 2, 47-54.
5. (b) Sato, A.; Saruta, T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J. Int. Med. Res. 2001, 29, 13-21.
6. Pitt, B.; Zannad, F.; Remme, W. J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999, 341, 709-717.
7. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Eng. J. Med. 2003, 348, 1309-1321.
8. Delcayre, C.; Swynghedauw, B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J. Mol. Cell. Cardiol. 2002, 34, 1577-1584.
9. (a) Wehling, M. Specific, nongenomic actions of steroid hormones. Annu. Rev. Physiol. 1997, 59, 365-393.
10. (b) Lösel, R.; Wehling, M. Nongenomic actions of steroid hormones. Nat. Rev. Mol. Cell. Biol. 2003, 4, 46-55.
11. Chai, W.; Garrelds, I. M.; de Vries, R.; Batenburg, W. W.; van Kats, J. P.; Danser, A. H. J. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 2005, 46, 701-706.
12. Hartmann, R. W. Selective inhibition of steroidogenic P450 enzymes: Current status and future perspectives. Eur. J. Pharm. Sci. 1994, 2, 15-16.
13. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179.
14. Hartmann, R. W.; Müller, U.; Ehmer, P. B. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur. J. Med. Chem. 2003, 38, 363-366.
15. Ulmschneider, S.; Müller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Oberwinkler-Marchais, S.; Klein, C. D.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J. Med. Chem. 2005, 48, 1796-1805.
16. Ulmschneider, S.; Müller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W. Synthesis and evaluation of (pyridylmethylene) tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J. Med. Chem. 2005, 48, 1563-1575.
17. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Barassin, C.; Oberwinkler-Marchais, S.; Hartmann, R. W. Heteroaryl substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 2005, 48, 6632-6642.
18. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Oberwinkler-Marchais, S.; Hartmann, R. W. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 2006, 49, 2222-2231.
19. Taymans, S. E.; Pack, S.; Pak, E.; Torpy, D. J.; Zhuang, Z.; Stratakis, C. A. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J. Clin. Endocrinol. Metab. 1998, 83, 1033-1036.
20. (a) Cavalli, A.; Bisi, A.; Bertucci, C.; Rosini, C.; Paluszcak, A.; Gobbi, S.; Giorgio, E.; Rampa, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Hartmann, R. W.; Recanatini, M. Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J. Med. Chem. 2005, 48, 7282-7289.
21. (b) Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J. Med. Chem. 2006, 49, 4777-4780.
22. Ulmschneider, S.; Negri, M.; Voets, M.; Hartmann, R. W. Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorg. Med. Chem. Lett. 2006, 16, 25-30.
23. (a) Richmond, N. J.; Abrams, C. A.; Wolohan, P. R.; Abrahamian, E.; Willett, P.; Clark, R. D. GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J. Comput.-Aided Mol. Des. 2006, 20, 567-587.
24. (b) Shepphird, J. K.; Clark, R. D. A marriage made in torsional space: Using GALAHAD models to drive pharmacophore multiplet searches. J. Comput. Aided Mol. Des. 2006, 20, 763-771.
25. Gillet, V. J.; Willett, P.; Fleming, P. J.; Green, D. V. S. Designing focused libraries using MoSELECT. J. Mol. Graph. Model. 2003, 20, 491-498.
26. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
27. Chowdhury, S.; Georghiou, P. E. Synthesis and properties of a new member of the calixnaphthalene family: A C2-symmetrical endocalix[4]naphthalene. J. Org. Chem. 2002, 67, 6808-6811.
28. Bengtson, A.; Hallberg, A.; Larhed, M. Fast synthesis of aryl triflates with controlled microwave heating. Org. Lett. 2002, 4, 1231-1233.
29. Appukkuttan, P.; Orts, A. B.; Chandran, R. P.; Goeman, J. L.; van der Eycken, J.; Dehaen, W.; van der Eycken, E. Generation of a small library of highly electron-rich 2-(hetero)aryl-substituted phenethylamines by the Suzuki-Miyaura reaction: A short synthesis of an apogalanthamine analogue. Eur. J. Org. Chem. 2004, 3277-3285.
30. Miller, L. E.; Hanneman, W. W.; St. John, W. L.; Smeby, R. R. The reactivity of the methyl group in 2-methyl-3-nitronaphthalene. J. Am. Chem. Soc. 1954, 76, 296-297.
31. Wu, K.-C.; Lin, Y.-S.; Yeh, Y.-S.; Chen, C.-Y.; Ahmed, M. O.; Chou, P.-T.; Hon, Y.-S. Design and synthesis of intramolecular hydrogen bonding systems. Their application in metal cation sensing based on excited-state proton transfer reaction. Tetrahedron 2004, 60, 11861-11868.
32. Brown, H. C.; Narasimhan, S.; Choi, Y. M. Selective reductions. 30. Effect of cation and solvent on the reactivity of saline borohydrides for reduction of carboxylic esters. Improved procedures for the conversion of esters to alcohols by metal borohydrides. J. Org. Chem. 1982, 47, 4702-4708.
33. Einhorn, J.; Einhorn, C.; Ratajczak, F.; Pierre, J.-L. Efficient and highly selective oxidation of primary alcohols to aldehydes by N-chlorosuccinimide mediated by oxoammonium salts. J. Org. Chem. 1996, 61, 7452-7454.
34. Parikh, J. R.; Doering, W. v. E. Sulfur trioxide in the oxidation of alcohols by dimethyl sulfoxide. J. Am. Chem. Soc. 1967, 89, 5505-5507.
35. Ono, A.; Suzuki, N.; Kamimura, J. Hydrogenolysis of diaryl and aryl alkyl ketones and carbinols by sodium borohydride and anhydrous aluminum(III) chloride. Synthesis 1987, 736-738.
36. Bieg, T.; Szeja, W. Removal of O-benzyl protective groups by catalytic transfer hydrogenation. Synthesis 1985, 76-77.
37. Li, X.; Hewgley, J. B.; Mulrooney, C. A.; Yang, J.; Kozlowski, M. C. Enantioselective oxidative biaryl coupling reactions catalyzed by 1,5-diazadecalin metal complexes: efficient formation of chiral functionalized BINOL derivatives. J. Org. Chem. 2003, 68, 5500-5511.
38. Stoner, E. J.; Cothron, D. A.; Balmer, M. K.; Roden, B. A. Benzylation via tandem Grignard reaction-iodotrimethylsilane (TMSI) mediated reduction. Tetrahedron 1995, 51, 11043-11062.
39. Cain, G. A.; Holler, E. R. Extended scope of in situ iodotrimethylsilane mediated selective reduction of benzylic alcohols. Chem. Commun. 2001, 1168-1169.
40. (a) Nakamura, H.; Wu, C.; Inouye, S.; Murai, A. Design, synthesis, and evaluation of the transition-state inhibitors of coelenterazine bioluminescence: probing the chiral environment of active site. J. Am. Chem. Soc. 2001, 123, 1523-1524.
41. (b) Gribble, G. W.; Leese, R. M.; Evans, B. E. Reactions of sodium borohydride in acidic media. IV. Reduction of diarylmethanols and triarylmethanols in trifluoroacetic acid. Synthesis 1977, 172-176.
42. (a) Denner, K.; Bernhardt, R. Inhibition studies of steroid conversions mediated by human CYP11B1 and CYP11B2 expressed in cell cultures. In Oxygen Homeostasis and Its Dynamics, 1st ed.; Ishimura, Y., Shimada, H., Suematsu, M., Eds.; Springer-Verlag: New York, 1998; pp 231-236.
43. (b) Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells. Endocr. Res. 1995, 21, 443-448.
44. (c) Böttner, B.; Denner, K.; Bernhardt, R. Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. Eur. J. Biochem. 1998, 252, 458-466.
45. Lamberts, S. W.; Bruining, H. A.; Marzouk, H.; Zuiderwijk, J.; Uitterlinden, P.; Blijd, J. J.; Hackeng, W. H.; de Jong, F. H. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro. J. Clin. Endocrinol. Metab. 1989, 69, 896-901.
46. Demers, L. M.; Melby, J. C.; Wilson, T. E.; Lipton, A.; Harvey, H. A.; Santen, R. J. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J. Clin. Endocrinol. Metab. 1990, 70, 1162-1166.
47. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene type aldosterone synthase inhibitors: Influence of heteroaryl derivatization on potency and selectivity. J. Med Chem. 2008, 15, 5064-5074.
48. (a) Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17α-hydroxylase-C17, 20-lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450- reductase in Escherichia coll J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63.
49. (b) Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent nonsteroidal CYP17 inhibitors as potential metabolites and evaluation of their activity by a noncellular assay using recombinant enzyme. J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32.
50. Thompson, E. A.; Siiteri, P. K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 1974, 249, 5364-5372.
51. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones. J. Med. Chem. 1986, 29, 1362-1369.
52. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P4502C9 with bound warfarin. Nature 2003, 424, 464-468.
53. Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 2002, 16, 129-149.
54. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
55. Rarey, M.; Kramer, B.; Lengauer, T. Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention. J. Comput.-Aided Mol. Des. 1997, 11, 369-384.